Hanvon Technology Co., Ltd. 2025 Annual Independent Director Performance Report (Gao Yansha)
To the esteemed shareholders and shareholder representatives:
Hello everyone!
As an independent director of Hanvon Technology Co., Ltd. (hereinafter referred to as the "Company"), I have strictly followed the "Administrative Measures for Independent Directors of Listed Companies," "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guidelines No. 1 - Normative Operation of Main Board Listed Companies," and other laws and regulations, as well as the Company's "Articles of Association" and "Work Rules for Independent Directors." With the principles of objectivity, fairness, and independence, I have diligently performed my duties, actively exercised my role as an independent director, and protected the overall interests of the Company and the legitimate rights and interests of all shareholders, especially small and medium shareholders. The summary of my performance of independent director duties in 2025 is as follows:
I. Basic Information of Independent Director
Gao Yansha: Female, born in 1963, Chinese national, with no permanent overseas residency, holding a postgraduate degree in cardiovascular medicine. From 1986 to 1989, she served as a resident physician in the Department of Cardiovascular Medicine at the Third Clinical Hospital of Jilin University. From 1992 to the present, she has served successively as attending physician, associate chief physician, and chief physician in the Department of Cardiology at Beijing Friendship Hospital. Concurrently, she holds visiting professorships at Peking University Health Science Center and Beijing University of Chinese Medicine. She is an expert in the professional fields of cardiovascular diseases, hypertension, coronary heart disease, and dyslipidemia, with rich clinical experience and profound expertise. She is currently an independent director of the Company.